Literature DB >> 442328

Two new, direct, and specific methods of acid phosphatase determination. National field trial.

Z Wajsman, T M Chu, J Saroff, N Slack, G P Murphy.   

Abstract

A national study of the new specific assays for prostatic acid phosphatase was conducted by the National Prostatic Cancer Project. The results of the study have confirmed that the counterimmunoelectrophoretic method is easily reproducible, highly specific, and sufficiently sensitive. Based on tests as performed by different institutions, the counterimmunoelectrophoretic (CIEP) method was also shown to have high reproducibility and was found to be of much greater sensitivity than the conventional biochemical methods for the detection of earlier stages of prostatic cancer. The national study of the radioimmunoassay (RIA) has shown that although being a highly sensitive method, it could not be readily distributed at this time from one specialized center. It requires highly specific, expensive technical assistance and is not yet available nationwide. CIEP is recommended at this time to be used as the preferred method in the evaluation and diagnosis of prostatic cancer. The value of counterimmunoelectrophoresis in detecting early prostatic cancer as a screening method is promising, but still under study.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 442328     DOI: 10.1016/0090-4295(79)90003-7

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  3 in total

1.  Pathology-Epitomes of Progress: Prostatic Acid Phosphatase (Male PAP).

Authors:  F M Finck
Journal:  West J Med       Date:  1980-04

2.  Radioimmunoassay (RIA) for prostatic acid phosphatase in patients with prostatic carcinoma.

Authors:  F M Debruyne; P J van Munster; J C van Groeninghen; W J Kirkels
Journal:  Urol Res       Date:  1984

3.  Trial of specific antigen-mediated leukocyte adherence inhibition test in patients with chronic active hepatitis and hepatitis B carrier.

Authors:  Y I Oh; S H Song; W H Kim; K H Cho; J K An; D S Ahn
Journal:  Korean J Intern Med       Date:  1986-07       Impact factor: 2.884

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.